Zoonotic Hookworm Infection and Cutaneous Larva Migrans
Zoonotic hookworm infection, CLM. Image credits: CDC Zoonotic hookworm infection in humans, commonly presenting as cutaneous larva migrans (CLM), occurs when hookworm larvae, typically from animals like dogs or cats, penetrate human skin. Primarily caused by Ancylostoma braziliense, the larvae migrate through the epidermis, leading to raised, erythematous tracks that often cause intense itching. While […]
The PLF C Diff Summit and Lobby Day
The Peggy Lillis Foundation is hosting its annual National C diff Summit, which is going to be held on Monday, March 31, at the Kellogg Conference Hotel at Gallaudet University in Washington DC. The annual event brings together clinicians, industry, C diff patients, caregivers and other stakeholders. This year’s Summit will feature scientific updates in […]
First-in-Human Study of Long-Acting Injectable HIV Nanoparticle Combination Therapy
Rachel A Bender Ignacio, MD, MPH Image credits: UW UMedicine A first-in-human study has evaluated the safety and pharmacokinetics of a new long-acting injectable antiretroviral therapy (LA-ART), developed as part of the Targeted Long-Acting Combination Antiretroviral Therapy (TLC-ART) Program, a collaboration between US research institutions, including the University of Washington and the National Institute of […]
bioMérieux Receives FDA 510(k) Clearance for its Vitek Compact Pro ID/AST system
Yesterday, bioMérieux announced the FDA cleared the company’s Vitek Compact Pro ID/AST system to be utilized for microorganism identification (ID) and antibiotic susceptibility testing (AST). This system looks to help clinical labs identify infectious diseases and combat antimicrobial resistance, as well as industrial laboratories to identify contaminants for ensuring consumer safety. 1 The Vitek Compact […]
FDA Mid-Month ID Food Recall Safety Updates
Product image Image credits: FDA AKT Trading Inc Recalls Prepared Vegetable Products Due to Clostridium Botulinum Risk AKT Trading Inc of Torrance, CA, recalls prepared vegetable products manufactured by Choshiya Honten Co, Ltd due to potential Clostridium botulinum contamination. The absence of the “Keep Refrigerated” label increases the risk of bacterial growth when stored at […]
Phase 2 Study Shows Efficacy of Six-Month Regimen of Lenacapavir, Teropavimab, and Zinlirvimab for HIV-1
At CROI 2025, Onyema Ogbuagu, MBBCh, FACP, FIDSA, associate professor at Yale School of Medicine, presented key findings from a Phase 2 study evaluating the efficacy and safety of switching to lenacapavir (LEN), teropavimab (TAB), and zinlirvimab (ZAB) (LTZ) every 6 months (Q6M) compared to staying on a stable baseline oral regimen (SBR) in virologically […]
Fear, Misconceptions Discourage International Hepatitis B and C Testing
In a large survey conducted across Africa, Asia, and Latin America, nearly a third of respondents said they had no interest in getting tested for hepatitis B virus (HBV) or hepatitis C virus (HCV). More than half of the respondents said they did not believe they were at risk for these viruses. These results offer […]
B/F/TAF Achieves Sustained HIV and HBV Suppression
At CROI 2025, Anchalee Avihingsanon, MD, PhD, principal investigator of the ALLIANCE study and researcher at the HIV-NAT at the Thai Red Cross AIDS Research Centre in Bangkok, Thailand, discussed findings from the ALLIANCE trial. This Phase 3 study evaluated the efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) compared to dolutegravir + emtricitabine/tenofovir disoproxil fumarate […]
Lassa Fever Vaccine Study Enrollment Begins
Scanning electron micrograph of Lassa virus budding off a cell. Lassa virus (LASV) is an arenavirus that causes Lassa hemorrhagic fever, a type of viral hemorrhagic fever (VHF) in humans and other primates.Image Credit: NIAID NIH announced today that enrollment has begun for participants in a Lassa fever vaccine study at the University of Maryland […]
Immunocore Reports 2/5 Participants Achieve Viral Control and HIV Reservoir Reduction Across 3 Dose Cohorts of IMC-M113V
Immunocore Holdings plc presented early findings from the multiple ascending dose (MAD) phase of its Phase 1/2 STRIVE trial for IMC-M113V at CROI 2025 in San Francisco, California. The data suggest that IMC-M113V, a T cell receptor bispecific therapy, is well tolerated and demonstrates signs of dose-dependent viral control after antiretroviral treatment (ART) interruption. The […]
